Musshoff F, Madea B
Institut für Rechtsmedizin, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Clin Chem Lab Med. 1998 Oct;36(10):803-8. doi: 10.1515/CCLM.1998.142.
Ninety eight urine samples were analysed with an immunoassay benzodiazepine kit. A total of 68 urine specimens that were presumptively positive for benzodiazepines were evaluated by the REMEDi HS urine benzodiazepine assay (BIO-RAD, Munich, Germany). Of this number, 53 (78%) specimens were found by REMEDi to contain one or more benzodiazepines or their metabolites, and 15 (22%) were found to be negative. From the discordant group of 15 samples, eight were found to be negative using conventional chromatographic procedures (HPLC or GC/MS), while seven contained one or more benzodiazepines or metabolites, each of which were below the individual cut-off level specified by the manufacturer. Additionally 30 urine specimens that were negative for benzodiazepines using immunoassay were also tested by REMEDi. Two samples were found to be positive. These results could not be confirmed by other chromatographic techniques. The REMEDi HS benzodiazepine assay can be a very useful complementary technique in the clinical/forensic toxicology laboratory, especially for the identification of the parent benzodiazepines administered. The assay provides a rapid result in emergency situations and is useful in confirmation of preliminary positive immunoassay results.
使用免疫分析苯二氮䓬试剂盒对98份尿液样本进行了分析。通过REMEDi HS尿液苯二氮䓬分析（德国慕尼黑伯乐公司）对总共68份推测为苯二氮䓬阳性的尿液标本进行了评估。在这些样本中，REMEDi检测发现53份（78%）标本含有一种或多种苯二氮䓬或其代谢物，15份（22%）为阴性。在15份结果不一致的样本中，使用传统色谱法（高效液相色谱法或气相色谱/质谱联用）检测发现8份为阴性，而7份含有一种或多种苯二氮䓬或代谢物，且每种均低于制造商规定的各自临界值水平。此外，还对30份使用免疫分析检测为苯二氮䓬阴性的尿液标本进行了REMEDi检测。发现两份样本为阳性。这些结果无法通过其他色谱技术得到证实。REMEDi HS苯二氮䓬分析在临床/法医毒理学实验室中可能是一种非常有用的补充技术，尤其对于所服用母体苯二氮䓬的鉴定。该分析在紧急情况下能快速得出结果，且有助于确认免疫分析初步阳性结果。
